Bluebird Bio announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher, or PRV, for $95M. Bluebird bio was granted two PRVs upon the FDA approvals of Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions and Skysona for the treatment of early, active cerebral adrenoleukodystrophy, on August 17, 2022 and September 16, 2022 respectively. On December 29, 2022, Bluebird closed the sale of its first PRV for $102M. Bluebird received a payment of $95M upon closing of the transaction, which occurred simultaneously with the parties entering into the agreement. Jefferies acted as the exclusive financial advisor to bluebird for this transaction.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLUE:
- Bluebird Bio appoints Joseph Vittiglio, JD, chief business and legal officer
- Bluebird Bio completes sale pf PRV to Argenx
- FDA removing lovo-cel partial hold a positive for Bluebird, says Morgan Stanley
- Bluebird Bio reports FDA lifts clinical hold on lovotibeglogene autotemcel study
- Bluebird Bio to sell Zynteglo PRV for $102M